左心室透静功能障碍与心力衰竭患者心力衰竭患者心力衰竭患者心力衰竭患者心力衰竭患者心力衰竭患者心力衰竭患者心力衰竭患者心力衰竭患者心力衰竭患者心力衰竭患者心力衰竭患者心力衰竭患者心力衰竭患者心力衰竭患者心力衰竭患者心力衰竭患者心力衰竭患
Sophia K Khaidirman1, Harris Hasan1, Cut A Andra1
1Department of Cardiology and Vascular Medicine, Faculty of Medicine, Universitas Sumatera Utara, Medan, Indonesia.
Narra J
|September 16, 2024
概括
左心室透静功能障碍的严重程度显著影响心力衰竭患者的生命质量 (QoL),心力衰竭患者心力衰竭患者心力衰竭患者心力衰竭患者心力衰竭患者心力衰竭患者心力衰竭患者心力衰竭患者心力衰竭患者心力衰竭患者心力衰竭患者心力衰竭患者心力衰竭患者心力衰竭患者心力衰竭患者心力衰竭患者心力衰竭患者心力衰竭患者心力衰竭患者心力衰竭患者心力衰竭患者心力衰竭患者心力衰竭患者心力衰竭患者心力衰竭患者心力衰竭患者心力衰竭患者心力衰竭患者心力衰竭患者心力衰竭患者心力衰竭患者心力衰竭患者心力衰竭患者心力衰竭患者心力衰竭患者心力衰竭患者心力衰竭患者心力衰竭患者心力衰竭患者心力衰竭 解决腹功能障碍对于改善HFrEF患者的QoL至关重要.
科学领域:
- 心脏病学 心脏病学
- 内部医学 内部医学
- 临床研究 临床研究
背景情况:
- 降低射出分数 (HFrEF) 的心力衰竭通常以左心室 (LV) 扩张功能障碍为特征.
- 静脉缩功能障碍显著导致HFrEF患者的生活质量 (QoL) 降低.
研究的目的:
- 在HFrEF患者中调查LV腹功能障碍和QoL等级之间的关联.
- 确定在HFrEF中改善患者结果的潜在目标.
主要方法:
- 追溯队列研究包括96名HFrEF患者 (射出分数≤40%).
- 心声扫描评估了使用E/A比率,E/e'比率,TR Vmax和LAVI.使用的LV腹筋功能障碍严重程度 (I,II,III级).
- 使用明尼苏达州生活与心力衰竭问卷 (MLHFQ) 评估生活质量 (QoL).
主要成果:
- 发现 LV 透静功能障碍的严重程度与 QoL (p=0.040) 之间存在显著的关系.
- 80.2%的患者报告了良好的QoL,而19.8%的人报告了不良的QoL.
- 较高程度的扩张性功能障碍与较差的QoL相关.
结论:
- 静脉缩功能障碍的程度是HFrEF患者的QoL的一个重要决定因素.
- 综合性管理策略应解决 LV 扩张功能障碍,以提高 HFrEF 中的 QoL.
- 需要进一步研究HFrEF中扩张性功能障碍的向治疗方法.
相关概念视频
01:17Pathophysiology of Heart Failure
1.5K
Heart failure (HF) is a progressive syndrome involving ventricles that leads to inadequate cardiac output. It can be classified based on location and output or ejection fraction. Ejection fraction (EF) is an essential measurement in the diagnosis and surveillance of HF. Reduced EF corresponds to systolic heart failure (HFrEF). However, HF with preserved ejection fraction (HFpEF) is becoming increasingly prevalent. Also known as diastolic HF, this form of HF is related to aging. The...
1.5K
01:26Imbalances in Cardiac Output
1.4K
The heart's primary function is to pump blood throughout the body, maintaining a balance between blood sent out (cardiac output) and blood returning (venous return). If this balance is disrupted, it can result in congestive heart failure (CHF), a severe condition where the heart becomes an inefficient pump, leading to inadequate blood circulation.
CHF can occur due to the failure of either side of the heart. Left-side failure leads to pulmonary congestion—the right side continues to send...
CHF can occur due to the failure of either side of the heart. Left-side failure leads to pulmonary congestion—the right side continues to send...
1.4K
01:22Heart Failure Drugs: Diuretics
350
Heart failure and kidney perfusion are interconnected in a complex way. Reduced renal perfusion and venous congestion are two significant factors that contribute to renal dysfunction in heart failure. The kidneys, primarily responsible for fluid balance in the body, are adversely affected due to compromised cardiac output and increased venous pressure. In response to reduced renal perfusion, the kidneys activate neurohumoral mechanisms to restore balance. However, these mechanisms can be...
350
01:17Imaging Studies for Cardiovascular System I:Echocardiography
299
Cardiac imaging studies encompass a wide range of noninvasive and minimally invasive techniques designed to visualize the heart's structure and function in detail. One such technique is echocardiography, which uses high-frequency ultrasound waves to produce detailed images of the heart, known as echocardiograms.
Indications: Echocardiography is utilized to diagnose heart failure, valve disorders, and myocardial infarction. It also assesses cardiac structures' size, shape, and motion,...
Indications: Echocardiography is utilized to diagnose heart failure, valve disorders, and myocardial infarction. It also assesses cardiac structures' size, shape, and motion,...
299
01:26Heart Failure Drugs: Inhibitors of Renin-Angiotensin System
398
The activation of the sympathetic nervous system and the renin-angiotensin-aldosterone system (RAAS) contributes to cardiac remodeling, and inhibiting the RAAS is a pharmacological target in heart failure management. As a result, neurohumoral modulation is a crucial treatment principle for managing heart failure. This approach involves using medications like ACE inhibitors (ACEIs), angiotensin receptor blockers (ARBs), β-blockers, mineralocorticoid receptor antagonists (MRAs), and neutral...
398